Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interleukin-2 SA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Interleukin-2 SA | DRUG | HAART and Bay 50-4798 |
| HAART | DRUG | HAART alone |
Inclusion Criteria: * Documented HIV infection (positive enzyme linked immuno assay (EIA) confirmed by Western Blot). * Age greater than or equal to 18 years. * Plasma HIV viral load less than 10,000 copies/ml (by bDNA assay or less than 14,000 copies/ml by RT-PCR) on at least 2 occasions within 8 ...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Interleukin-2 SA is an investigational small molecule being developed for the treatment of HIV infections. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and its safety and efficacy are still being evaluated in clinical trials.
Interleukin-2 SA is being developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker symbol BAYRY. The drug is currently in Phase 1 clinical development for the treatment of HIV infections.
Interleukin-2 SA is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of HIV infections and has not yet received regulatory approval. One Phase 1 clinical trial has been completed for this drug.
Interleukin-2 SA has one completed Phase 1 clinical trial, identified as NCT00059462, titled "Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection." This randomized, double-blind, active-controlled trial enrolled 56 participants with HIV infections across the United States, France, and the United Kingdom.
Yes, Interleukin-2 SA is also known as BAY 50-4798. In clinical trial NCT00059462, the drug is referred to as BAY 50-4798, and it is being studied for the treatment of HIV infections.